Novavax Reports Second Quarter 2009 Financial Results
... will be formed and funded to support Phase III clinical development and other studies necessary to ... flu vaccine candidate; Initiate a Phase II clinical study of our trivalent seasonal flu vaccine in ... outside testing costs associated with continuing clinical trials, preclinical testing, process development, ...Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... alliances that will allow us to pursue future clinical and non-clinical trials of CPP-109." "We are currently evaluating the data from our Phase II clinical trial evaluating the use of CPP-109 for the ... the development of CPP-109, including the clinical and non-clinical trials that will be required for ...NeurogesX Reports Second Quarter 2009 Results
... the topical agent used as a pretreatment in the clinical development program. The study, conducted in ... in PHN, but continued to defer non-clinical and clinical expenses for all other development programs in ... the companies would collaborate on Phase 3 clinical development. NeurogesX is also seeking ...Viral Genetics Creates Subsidiary to Develop Cancer Therapy
... knowledge and tools to turn this concept into a clinical reality." Dr Karen Newell and her team at ... to optimize therapies based on TNP for future clinical trials. Viral Genetics believes that its ... projections, budgets, milestone timelines, clinical development, regulatory approvals, and other ...AutoImmune Inc. Reports 2009 Second Quarter Financial Results
... announced that they would discontinue ongoing clinical trials and review available data. Chairman of ... 1995. These statements include statements about clinical trials and studies and future sales, royalties ... but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third ...ThermoGenesis Announces Expanded Collaboration With Celling Technologies
... and Celling will share in the funding for clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q Systems ... orthopedic applications. Incremental funding for clinical studies will be provided by ThermoGenesis and ...GenVec Reports Second Quarter 2009 Financial Results
... at the annual meeting of the American Society for clinical Oncology. The poster , entitled "Multi-Center Randomized Controlled Phase III clinical Trial using TNFerade(TM) with Chemoradiation in ... product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic ...ThermoGenesis Provides Update on Fiscal 2009 Results
... of this agreement include shared funding for clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q Systems ... Celling will be responsible for coordinating the clinical studies. The Company believes the results of ...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... which clear the way for our Phase 2 and Phase 3 clinical programs; our expectation that our partner Roche ... 10 percent, reflecting completion of the CAPACITY clinical trials in early 2009, partially offset by ... million and $5.6 million, respectively. clinical Development Highlights Pirfenidone: ...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
... as expenses associated with the company's new clinical Laboratory Improvement Amendment (CLIA) certified ... make this new offering an ideal system for use in clinical laboratories. OncoCarta Panel - The ... work. The company is also sponsoring a number of clinical studies through independent third parties, the ...OncoGenex Reports Second Quarter 2009 Financial Results
... follow-up for previously announced phase 2 clinical trials of OGX-011; - completion of its phase 1 clinical trial evaluating OGX-427 as a monotherapy ... initiation of an investigator-sponsored phase 1 clinical trial evaluating OGX-427 treatment in ...Telik Announces Second Quarter 2009 Financial Results
... restructuring in February 2009, reduced research, clinical trial and related expenses and lower stock ... due to lower headcount, reduced research and clinical trial expenses and lower stock-based compensation ... Telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on ...Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
... to working with our team to create an optimum clinical development plan for our novel drug candidate, ... our collaborator Genentech's ongoing Phase II clinical trials of GDC-0449, a Hedgehog Pathway Inhibitor, ... while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and ...Repligen Reports First Quarter Fiscal Year 2010 Financial Results
... associated with advancement of both our Phase 3 clinical trial of RG1068 for pancreatic imaging, and our Phase 2b clinical trial of RG2417 for bipolar depression, as well ... We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, ...iCardiac Expands Sales and Marketing Team
... in operations and business development in the clinical research industry, specializing in centralized ... and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better ... has been used for over a decade in cardiac clinical trials conducted for and by leading large and ...NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
... the PDUFA date for the NDA; acceptance of clinical trial or other data, analysis or information by ... outcomes and interpretation of the results of clinical trials; and plans for entry into a U.S. ... but not limited to; positive results in clinical trials may not be sufficient to obtain FDA ...Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
... Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia ... KRX-0401 has demonstrated both safety and clinical efficacy in numerous adult and pediatric tumor ... cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a ...Amicus Therapeutics Announces Second Quarter 2009 Financial Results
... patients who suffer with Fabry disease." clinical Program Updates Amigal (TM) ... It is expected that approximately 30 clinical sites worldwide will participate in this trial. ... treatment of Gaucher Disease A Phase 2 clinical trial of the Company's investigational drug ...Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
... development costs as the company completed its clinical development program for Acetavance in early 2009 ... the FDA may require Cadence to perform additional clinical trials, studies or other activities, or request ... where Acetavance is manufactured, or Cadence's clinical trial sites, may raise issues that must be ...Pharmasset to Present at Canaccord Adams Conference
... for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus ... and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, ...GeoVax Labs, Inc. Provides Clinical Studies Update
... updates on its ongoing and planned human clinical trials. "We have two main areas of focus ... Labs, Inc. "The results of the early Phase 1 clinical work for the preventative version of the vaccine ... up to another level of analysis, Phase 2a human clinical trial. This trial was initiated by the HIV ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... as planned. We are also initiating Phase 2 pilot clinical trials to assess the efficacy and safety of ... safety concerns regarding INTUNIV, request new clinical data or additional analyses in the Complete ... adults - Shire is conducting Phase 2 pilot clinical trials to assess the efficacy and safety of ...Pharmacyclics, Inc. Rights Offering Oversubscribed
... our progress as we continue to produce important clinical results in the future." Subscription ... Pharmacyclics has four product candidates in clinical development and two product candidates in ... rights and simultaneously fast forward the clinical development and commercialization of its ....Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
... Recent Corporate Highlights clinical investigator, Thomas J. Louie, M.D., presented ... from Optimer's fidaxomicin North American Phase 3 clinical study for patients with Clostridium difficile infection at the European Congress of clinical Microbiology and Infectious Diseases meeting, ...Omeros Appoints New Vice President of Clinical Development
... R. Murray, M.D., Ph.D. as Vice President of clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product ...Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... approximately 680,000 lives. clinical Progress St. Gallen International ... targeted agents are currently being evaluated in clinical studies. ... Score(R) provided additional independent clinical value beyond standard measures. Completed ...Micromet Closes $80.5 Million Public Offering of Common Stock
... Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with ...Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
... of Diana Hausman, M.D., as Vice President, clinical Development at Oncothyreon. In this position, Dr. ... be responsible for planning and implementing the clinical development program for the Company's pipeline of ... Seattle, Washington, where she held a number of clinical research positions from 2005 to 2009, most ...VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
... The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. ...